Continuous Glucose Monitoring System (CGMS) in Type 2 Diabetic Patients Inadequately Controlled by Metformine Monotherapy; Analyze of Glycemic Profile Before and After Association of Glimepiride
Analyse the glucose profile, based on continuous glucose monitoring by CGMS, in type 2 diabetics inadequately controlled by metformin, before and after the addition of Glimepiride...
Brief Summary
Analyse the glucose profile, based on continuous glucose monitoring by CGMS, in type 2 diabetics inadequately controlled by metformin, before and after the addition of Glimepiride.
- Study Type: Interventional
- Study Design: Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention(s) in this Clinical Trial
- Drug: GLIMEPIRIDE
Outcome Measures for this Clinical Trial
Primary Measures
- Change in interstitial glucose levels between the observation and maintenance phases.
- Time Frame: The mean of 24 variations in average hourly glucose readings recorded by CGMS.
Safety Issue?: No
- Time Frame: The mean of 24 variations in average hourly glucose readings recorded by CGMS.
Secondary Measures
- HbA1c and fasting blood glucose levels.
- Time Frame: Measured in the observation and maintenance phases, and change between the two phases.
Safety Issue?: No
- Time Frame: Measured in the observation and maintenance phases, and change between the two phases.
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Men or women aged 35 to 70 years
- Having given their consent
- Type 2 diabetics (HBA1c greater than 6.5%
- Fasting glycaemia greater than 1.40 g/l) not controlled by Metformin for at least 6 weeks.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 35 Years
Maximum Age for this Clinical Trial: 70 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: Sanofi-Aventis Industry
Overall Clinical Trial Officials and Contacts
Nathalie Billon Study Director Sanofi-Aventis
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00633425
Study ID Number: HOE490B_4001
ClinicalTrials.gov Identifier: NCT00633425
Health Authority: France: Afssaps - French Health Products Safety Agency
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00633425
